Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib

Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudev, Naveen S., Larkin, James M.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210627/
https://www.ncbi.nlm.nih.gov/pubmed/22084622
http://dx.doi.org/10.4137/CMO.S7263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210627/
https://www.ncbi.nlm.nih.gov/pubmed/22084622
http://dx.doi.org/10.4137/CMO.S7263

Ejemplares similares